Skip to main content

Table 1 Baseline characteristics of patients

From: The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy

Characteristics

Supportive Care (n = 71)

Supportive care plus fluticasone (n = 71)

P

Age (y)

39.3 ± 10.1

39.6 ± 10.5

0.9

BMI (kg/m2)

23.46 ± 4.16

23.96 ± 3.42

0.4

Female, n(%)

14 (19%)

18 (25%)

0.4

Smoking, n(%)

16 (22%)

14 (19%)

0.7

Systolic pressure

127 ± 8.4

125 ± 8.7

0.2

Serum creatinine (µmol/L)

120.2 ± 30.6

127.5 ± 35.7

0.2

eGFR (ml/min/1.73m2)

86.42 ± 33.93

84.2 ± 32.2

0.7

Daily urinary protein (g/d)

1.9 ± 0.4

1.8 ± 0.7

0.3

UACR (g/g)

0.88 ± 0.6

0.90 ± 0.5

0.5

Oxford histologic score

   

 M0/M1

9/17

12/16

0.5

 E0/E1

16/10

20/8

0.4

 S0/S1

3/23

12/16

0.01

 T0/T1

13/8

14/12

0.6

Therapy with ACEI

25

22

0.6

Therapy with ARB

46

49

0.6

  1. BMI, body mass index; eGFR, estimated glomerular filtration rate; UACR, urinary albumin-to-creatinine ratio; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker